|Last Price$7.25||Day Change (%)-2.42%|
|Open Price$7.40||Day Change ($)-0.18|
|Day Range7.23–7.43||52-Week Range3.05–8.61|
As of Fri 4/24/2015 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.